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AbstrAct
Objective The prognostic significance of obstructive sleep 
apnea (OSA) in patients with acute coronary syndrome 
(ACS) according to diabetes mellitus (DM) status remains 
unclear. We aimed to elucidate the association of OSA with 
subsequent cardiovascular events in patients with ACS 
with or without DM.
Research design and methods In this prospective cohort 
study, consecutive eligible patients with ACS underwent 
cardiorespiratory polygraphy between June 2015 and May 
2017. OSA was defined as an Apnea Hypopnea Index ≥15 
events/hour. The primary end point was major adverse 
cardiovascular and cerebrovascular events (MACCEs), 
including cardiovascular death, myocardial infarction, 
stroke, ischemia- driven revascularization, or hospitalization 
for unstable angina or heart failure.
Results Among 804 patients, 248 (30.8%) had DM and 
403 (50.1%) had OSA. OSA was associated with 2.5 times 
the risk of 1 year MACCE in patients with DM (22.3% vs 
7.1% in the non- OSA group; adjusted HR (HR)=2.49, 95% 
CI 1.16 to 5.35, p=0.019), but not in patients without DM 
(8.5% vs 7.7% in the non- OSA group, adjusted HR=0.94, 
95% CI 0.51 to 1.75, p=0.85). Patients with DM without 
OSA had a similar 1 year MACCE rate as patients without 
DM. The increased risk of events was predominately 
isolated to patients with OSA with baseline glucose or 
hemoglobin A1c levels above the median. Combined OSA 
and longer hypoxia duration (time with arterial oxygen 
saturation <90%>22 min) further increased the MACCE 
rate to 31.0% in patients with DM.
Conclusions OSA was associated with increased risk of 
1 year MACCE following ACS in patients with DM, but not 
in non- DM patients. Further trials exploring the efficacy of 
OSA treatment in high- risk patients with ACS and DM are 
warranted.
InTROduCTIOn
Type 2 diabetes mellitus (DM) is associated 
with extensive coronary atherosclerosis1 and 
accelerated plaque progression.2–4 Compared 
with non- diabetics, patients with DM are 
known to have a higher risk of recurrent 
cardiovascular events after acute coronary 
syndromes (ACS).5–7 Obstructive sleep apnea 
(OSA) is an increasingly recognized chronic 
disorder in patients with ACS, with reported 
incidence of 36% to 63% across various 
ethnicities.8 Recent evidence indicates OSA 
initiates and exacerbates coronary atheroscle-
rosis,9–11 and predicts adverse cardiovascular 
outcomes post- ACS in the long run.12–16 Also, 
studies have shown the potential interaction 
between OSA and DM in glycemic control and 
the development of chronic diabetic compli-
cations.17–20 Whether the prognostic signifi-
cance of OSA in patients with ACS would vary 
according to DM status has not been char-
acterized. Given the shared mechanisms by 
OSA and DM in promoting atherosclerosis, 
we hypothesized that concomitant OSA and 
significance of this study
What is already known about this subject?
 ► Prior reports indicated that obstructive sleep apnea 
(OSA) may be associated with increased risk of re-
current cardiovascular events after acute coronary 
syndrome (ACS).
 ► Whether the prognostic significance of OSA in pa-
tients with ACS may be modified by diabetes melli-
tus (DM) status remains unclear.
What are the new findings?
 ► In this prospective cohort study involving 804 pa-
tients with ACS, OSA was associated with 2.5 times 
the risk of major adverse cardiovascular and cere-
brovascular events (MACCEs) in patients with DM, 
but not in patients without DM. patients with DM 
without OSA had a similar 1 year MACCE rate as pa-
tients without DM.
 ► The increased risk of adverse events was predom-
inately isolated to patients with OSA with poor glu-
cose control.
How might these results change the focus of 
research or clinical practice?
 ► The present study showed that OSA was only asso-
ciated with increased risk of adverse events follow-
ing ACS in patients with DM, therefore representing 
a high- risk subset most likely to respond to the 
intervention.
 ► Future trials evaluating the effects of OSA treatment 
in patients with DM and ACS are needed.
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DM might exert a synergistic deleterious effect increasing 
future cardiovascular risk. Therefore, we performed a 
large prospective cohort study and elucidated the asso-
ciation of OSA with subsequent cardiovascular events in 
patients with ACS in relation to diabetes status.
ReseaRCH desIgn and meTHOds
study design and participants
This was a prospective cohort study to evaluate the impact 
of OSA on cardiovascular outcomes in patients presenting 
with ACS stratified by diabetes. The study design has 
been described previously.21 In brief, from June 2015 
to May 2017, a total of 899 patients aged 18 years to 85 
years and admitted for ACS were consecutively enrolled 
and received overnight sleep study in the Emergency 
and Critical Care Center of Beijing Anzhen Hospital, 
Capital Medical University. Exclusions included cardio-
genic shock (n=5), cardiac arrest (n=6), malignancy 
(n=8), and failed sleep study (patients without adequate 
and satisfactory signal recording, n=13). This left 867 
patients with a successful sleep study. Next, patients with 
predominantly central sleep apnea (≥50% central events 
or a central Apnea Hypopnea Index (AHI) ≥10/hours, 
n=20) and those receiving regular continuous positive 
airway pressure (CPAP) therapy (>3 months, n=10) after 
discharge were excluded. Thirty- three patients were lost 
to follow- up and were excluded from the analysis. The 
final cohort included 804 patients. This study conformed 
to the STrengthening the Reporting of OBservational 
studies in Epidemiology guidelines, and was conducted 
in accordance with the amended Declaration of Helsinki. 
All patients provided written informed consent.
All patients received standard care during hospitalization 
according to current guidelines.22 23 Type 2 DM was iden-
tified by patient history, supported by treatment details. 
Glucose and hemoglobin A1c (HbA1c) levels were obtained 
from non- fasting venous blood samples at admission. We 
described clinical, demographic, angiographic and proce-
dural characteristics for each group according to DM status.
Overnight sleep study
The diagnosis of OSA was assessed by an overnight portable 
cardiorespiratory polygraphy (ApneaLink Air, Resmed, 
Australia) after clinical stabilization during hospitalization 
(median 2 days (1 to 3 days) after admission). Sleep studies 
were scored according to the American Academy of Sleep 
Medicine 2007 guidelines. Sleep studies of <3 hours of 
satisfactory signal recording were considered invalid and 
excluded from analysis. All studies were scored manually 
twice (by XW and JF), both of whom were blinded to the 
demographic and clinical characteristics. Further analysis 
was performed in cases of discrepancy by a senior consul-
tant in sleep medicine (YW). Nasal airflow, thoracoabdom-
inal movements, pulse oximetry, and snoring episodes were 
recorded. An apnea was defined as total cessation of airﬂow 
for ≥10 s (obstructive if thoracoabdominal movement was 
present, and central if thoracoabdominal movement was 
absent). A hypopnea was defined as an airflow reduction 
of 30% for ≥10 s and was associated with a drop in arterial 
oxygen saturation (SaO2) >4%. The total AHI was defined 
as the number of apneas and hypopneas per hour of total 
recording time. OSA was defined as AHI ≥15 events/hour. 
Patients with AHI <15 events/hour were considered as the 
non- OSA group. Patients with OSA (AHI ≥15), particularly 
those with excessive daytime sleepiness, were referred to 
the sleep center for further evaluation.
end points
The primary end point was major adverse cardiovascular and 
cerebrovascular event (MACCE), defined as a composite of 
cardiovascular death, myocardial infarction, stroke, ischemia- 
driven revascularization, or hospitalization for unstable 
angina or heart failure. Secondary end points included the 
components of primary end point, all- cause death, repeat 
revascularization, and a composite of all events. All end 
points were deﬁned according to the proposed deﬁnitions 
by the Standardized Data Collection for Cardiovascular 
Trials Initiative.24 Patients were followed up from the time of 
the sleep study and at 1 month, 3 months, 6 months, 1 year, 
and every 6 months thereafter. Clinical events were collected 
via clinic visit, medical records, or telephone calls and led by 
an investigator (SN) who was blinded to the patients’ sleep 
results. All clinical events were independently adjudicated 
by the clinical event committee blinded to the OSA and DM 
status. The committee also reviewed the source documents 
and established the necessity for hospital admission and/or 
revascularization.
statistical analyses
We reported the impact of OSA on MACCE and other 
cardiovascular events by DM status, the median of serum 
glucose (5.9 mmol/L), and the median of HbA1c (6.0%). 
Kaplan- Meier curves were plotted in OSA and non- OSA 
groups stratified by DM status, dichotomized serum 
glucose and HbA1c, and compared by log- rank test. The 
relationship between OSA and the end points by DM 
status were analyzed by Cox proportional hazard models. 
Baseline variables that were considered clinically relevant 
or that showed a univariate relationship with outcome 
were entered into multivariable Cox regression models. 
Variables for inclusion were carefully chosen, given the 
number of events available, to ensure parsimony of the 
final models. If a patient experienced more than one 
event, only the first event was included in the analysis. 
Adjusted HR with 95% CI was calculated.
Receiver operating curve (ROC) analyses were 
performed to identify parameters of OSA to predict 
MACCE in patients with DM. The optimal cut- off value 
was estimated by area under the curve (AUC) via Youd-
en’s Index (the maximum value of (sensitivity+speci-
ficity − 1)). We calculated event rates based on single or 
combined OSA characteristics.
Continuous variables were presented as mean±SD or 
median (first and third quartiles), and were compared 
by Student’s t- test or Mann- Whitney U test. Categorical 
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variables were shown as the number (percentage), and 
were compared using χ2 statistics or Fisher’s exact test, 
when appropriate. All analyses were conducted with SPSS 
V.22.0 (IBM SPSS, Armonk, New York, USA). A two- sided 
p value<0.05 was considered statistically significant.
ResulTs
Patients
A total of 804 patients (82.6% male; 57.5±10.2 years) 
was included in the final analysis. Of these, 248 (30.8%) 
had DM and 403 (50.1%) had OSA. Patients with DM 
were older, more likely to be female, and had a higher 
incidence of hypertension and hyperlipidemia, but were 
less likely to be current smokers. The prevalence of 
OSA was similar in both DM and non- DM groups. Sleep 
study results were comparable between DM and non- DM 
patients (online supplementary eTable 1).
The baseline characteristics of OSA and non- OSA 
groups according to DM status are presented in table 1 
and online supplementary eTable 2. Patients with OSA 
exhibited higher body mass index and waist- to- hip ratio 
in both subgroups. Baseline glucose and HbA1c levels 
tended to be higher in patients with OSA, irrespective 
of DM status. Multivessel disease was more frequent in 
the OSA group compared with the non- OSA group, with 
numerically more percutaneous coronary intervention 
(PCI) procedures in the OSA group. Other information 
was generally well matched between OSA and non- OSA 
patients in the DM and non- DM subgroups.
Outcomes of Osa versus non-Osa patients in relation to 
diabetes status and glucose control
Among patients with DM, the presence of OSA was strongly 
associated with a higher rate of MACCE compared with 
patients without OSA (22.3% vs 7.1%; HR=2.89, 95% CI 
1.36 to 6.17, p=0.006). In contrast, the incidence of 
MACCE was similar between OSA and non- OSA groups 
in patients without DM (8.5% vs 7.7%; HR=1.06, 95% CI 
0.59 to 1.90, p=0.85; table 2, figures 1A and 2). A similar 
finding was observed in multivariable Cox regression anal-
ysis (table 2). Patients with DM without OSA had a similar 
1 year rate of MACCE as all patients without DM (7.1% vs 
8.1%; HR=0.97, 95% CI 0.47 to 1.98, p=0.93). There was 
also no significant difference in the incidence of MACCE 
in DM and non- DM patients without OSA (7.1% vs 7.7%; 
HR=0.99, 95% CI 0.45 to 2.15, p=0.97). Conversely, in 
patients with OSA, the 1 year MACCE rate was greater in 
patients with DM compared with non- DM patients (22.3% 
vs 8.5%; HR=2.70, 95% CI 1.56 to 4.67, p<0.001). There 
was a trend towards increased risk of hospitalization for 
unstable angina in OSA versus non- OSA groups in patients 
with DM (table 2). Other crude number of events are listed 
in online supplementary eTable 3.
For patients with glucose levels above the median of 
5.9 mmol/L, the presence of OSA was associated with 
a higher incidence of MACCE compared with patients 
without OSA (17.4% vs 6.8%; HR=2.36, 95% CI 1.25 to 
4.45, p=0.008; figures 1B and 2). Likewise, an increased 
risk of MACCE was observed in the OSA group among 
patients with HbA1c levels above the median of 6.0% 
(18.4% vs 8.3%; HR=2.03, 95% CI 1.11 to 3.70, p=0.022; 
figures 1C and 2). In contrast, there were no significant 
differences in MACCE rates among patients with glucose 
or HbA1c lower than median levels (figure 2).
Osa-related characteristics to predict maCCe in patients with 
dm
ROC analysis was performed to identify OSA- related 
characteristics predictive of MACCE in patients with DM. 
The minimum SaO2 and the duration of time with SaO2 
<90% (TSA90) that predicted MACCE was a cut- off value 
of 80% (AUC=0.603; p=0.048) and 22 min (AUC=0.639; 
p=0.01), respectively. The rate of MACCE based on single 
or combined OSA characteristics is shown in figure 3. 
The MACCE rate increased to 31.0% with concomitant 
OSA and TSA90 >22 min, compared with 9.8% when both 
were absent (HR=3.39, 95% CI 1.73 to 6.66, p<0.001).
dIsCussIOn
The present analysis reveals a synergistic relationship 
between DM and OSA, such that patients with DM and 
OSA had a 2.5- fold higher rate of MACCE compared with 
patients with DM but without OSA after ACS onset. In 
contrast, among non- DM patients, the incidence of MACCE 
was similar between the OSA and non- OSA groups. The 
increased risk of adverse events was predominately isolated 
to OSA patients with poor glucose control. The presence 
of OSA combined with increased hypoxia duration further 
exacerbated this risk in patients with DM.
Several small observational studies have demonstrated 
the association between OSA and increased risk of adverse 
outcomes following ACS.12–14 Our study extends prior anal-
ysis by focusing on the role of OSA in a high- risk subset of 
patients with DM. The prevalence of OSA is high in patients 
with DM;18 25 26 both comorbidities accelerate progression 
of atherosclerosis,2 10 predisposing to recurrent events in 
those that develop ACS. In the present study, the presence 
of OSA significantly predicted subsequent cardiovascular 
events in patients with DM, but not in non- DM patients 
(consistent with the Sleep and Stent Study).27 Moreover, 
our study provided detailed information regarding glucose 
control and found that the increased risk of MACCE was 
observed only in patients with OSA with higher glucose 
or HbA1c levels. These results indicate that patients with 
combined OSA and DM represent a very high- risk group 
for future adverse events.
Emerging evidence has demonstrated a close rela-
tionship between OSA and incident diabetes.28 29 
OSA- mediated intermittent hypoxemia and sleep fragmen-
tation are likely contributing factors leading to abnormal 
glucose metabolism. Mechanistically, recurrent cycles of 
hypoxemia with reoxygenation promote oxidative stress, 
systemic inflammation, and endothelial dysfunction, all 
implicated in the pathogenesis of diabetes and related 
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Figure 1 Kaplan- Meier curves for MACCE in OSA versus non- OSA groups according to diabetes status and glucose 
control. The cumulative incidences of MACCE are shown in OSA and non- OSA groups, stratified on the basis of diabetes or 
no diabetes (A), glucose level above or below the median of 5.9 mmol/L (B), and HbA1c above or below the median of 6.0% 
(C). DM, diabetes mellitus; HbA1c, hemoglobin A1c; MACCE, major adverse cardiovascular and cerebrovascular event; OSA, 
obstructive sleep apnea.
macrovascular and microvascular complications.30 Note-
worthy, there is reverse causality between OSA and DM, 
as diabetes neuropathy may worsen OSA and nocturnal 
hypoxemia by affecting central control of respiration.31–33 
The significant interaction between OSA and DM may 
exert a synergistic effect to promote the development 
and progression of atherosclerosis and increase ischemic 
events in patients with ACS. In our study, the presence 
of OSA and DM was associated with a very high rate of 
multivessel disease. Patients with concomitant OSA and 
DM were at the highest risk of incurring a MACCE. The 
combination of OSA and increased hypoxia duration 
increased the MACCE rate to 31.0% in patients with DM.
Specifically, most events in this study were rehospital-
izations for unstable angina and repeat revascularization 
(mostly attributed to non- target vessels). Cardiovascular 
death, MI, and stroke were less common. Prior studies have 
demonstrated that long- term adverse outcomes in patients 
with DM were predominantly caused by new lesions in non- 
culprit vessels.34 Similarly, untreated OSA was also associ-
ated with increased risk of repeat revascularization (mainly 
in non- target lesions).35 Patients with OSA and DM, given 
shared mechanisms, are more prone to native plaque 
progression and subsequent cardiac ischemic events.
On the other hand, patients without DM represent a 
relatively low- risk subset compared with those with DM. 
According to intravascular ultrasound analysis, non- DM 
patients had fewer lesions across the coronary tree and 
had less necrotic core as well as a lower frequency of 
thin- cap fibroatheromas, indicating a lower risk of plaque 
vulnerability.36 37 Although OSA could promote oxidative 
stress and inflammatory responses, resulting in endothe-
lial dysfunction and reduction of repair capacity,38 it may 
have less effect in non- DM patients. In our study, OSA was 
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Figure 2 Outcomes of MACCE in OSA vs non- OSA groups 
according to diabetes status and glucose control.Shown 
are the crude incidences of MACCE, unadjusted HR, and 
95% CI in patients with OSA and non- OSA patients in each 
subgroup. HbA1c, hemoglobin A1c; MACCE, major adverse 
cardiovascular and cerebrovascular event; OSA, obstructive 
sleep apnea.
Figure 3 Rate of MACCE based on single or combined OSA characteristics in patients with diabetes. The best cut- off values 
of minimum SaO2 <80% and TSA90 >22 min were used in the adjusted Cox regression analysis. MACCE, major adverse 
cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea; SaO2, arterial oxygen saturation; TSA90, the duration 
of time with SaO2 <90%.
not associated with increased risk of cardiovascular events 
following ACS in non- DM patients, a finding also observed 
in another study including patients undergoing PCI.27 
Thus, it is more reasonable and clinically significant to 
screen for OSA in high- risk patients with ACS (DM, etc).
Currently, data from randomized controlled trials do not 
support a role of CPAP for reducing cardiovascular events 
among patients with established cardiovascular disease.39 40 
In the RICCADSA (Randomized Intervention with Contin-
uous Positive Airway Pressure in CAD and OSA) Study, 
224 non- sleepy patients with OSA and coronary artery 
disease (CAD) were randomized to CPAP or usual care. 
At a median follow- up of 57 months, no difference was 
found in a composite end point of repeat revascularization, 
MI, stroke, or cardiovascular death.39 The negative results 
may be partly explained by the fact that patients are under 
guideline- based optimal medical therapy, including inten-
sive antiplatelet therapy, and control of blood pressure, 
dyslipidemia, and glucose, which are also the intermediate 
mechanisms implicated in OSA.41 More importantly, the 
RICCADSA trial included the entire spectrum of patients 
with CAD, with only 25% of patients having DM, thereby 
limiting the sample to a potentially lower- risk group.39 In 
the present study, only patients with combined DM and 
OSA had a significantly increased risk of future events after 
ACS, therefore representing a high- risk subset most likely to 
respond to the intervention. Conversely, patients with DM 
without OSA had a similar prognosis as patients without 
DM (with or without OSA). The presence of OSA seems to 
be a key modifier contributing to the negative effect of DM 
in patients with ACS. Thus, for patients with ACS and DM, 
it is important to screen for OSA and intervention may be 
needed, although more trials evaluating the effects of OSA 
treatment in this high- risk subgroup are warranted.
study limitations
First, the size of the DM cohort with 248 patients was 
modest. However, the primary outcome showed a signif-
icant difference between the OSA and non- OSA groups 
in patients with DM. Also, the results based on glucose 
and HbA1c levels were consistent with the main findings. 
Second, the diagnosis of OSA was based on portable 
polygraphy, a method that may underestimate AHI due 
to overestimating actual sleeping time. Third, although 
OSA severity may be overestimated during the acute 
setting of ACS but not stable CAD,42–44 this is true for OSA 
assessment in the setting of any high- risk acute disease 
including heart failure. Additionally, the patients in our 
study received a sleep study after clinical stabilization 
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during hospitalization, minimizing the potential bias. 
Fourth, the overall sample was predominantly male and 
non- obese. Whether our findings may be extrapolated 
to the female or obese population is unknown. Finally, 
this study primarily recruited East- Asian patients. Studies 
pertaining to other ethnicities are needed.
COnClusIOns
The present study demonstrated that in high- risk 
patients with ACS and DM, the presence of OSA 
was associated with a higher incidence of MACCE 
compared with patients without OSA. The increased 
risk associated with OSA was not observed in non- DM 
patients. Moreover, the prognosis of patients with DM, 
but without OSA, was similar to patients without DM. 
Further randomized trials exploring the efficacy of 
OSA treatment in the high- risk population with both 
DM and ACS are highly warranted.
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